The Determination of Optimal Operating Condition For an Off-Grid Hybrid Renewable Energy Based Micro-Grid: A Case Study in Izmir, Turkey

Nowadays, off-grid systems, which do not require grid connection investment instead of grid connected systems, have become quite feasible. In this study, a feasibility analysis was carried out for a hybrid energy system using solar and wind energy sources to supply to uninterrupted electricity demand of a region with 100 villas in Izmir, Turkey. It has been shown that how changes cost of the hybrid energy system sizing according to the control strategies by using the HOMER software. In the paper, two different control strategies are determined as Cycle Charging (CC) and Load Following (LF), and then the control strategies are compared. According to the results obtained as a result of the simulations, it has been revealed that the research region to operate with CC can supply to the electrical energy demand with lower capacity system architecture. The CC was found to be more suitable for the research region than LF in terms of both Cost of Energy (COE) and Net Preset Cost (NPC)

INHERITED THROMBOPHILIA IN TURKISH WOMEN, AS A RISK FACTOR FOR ISCHEMIC PLACENTAL DISEASES

We aim to elucidate the link between inherited thrombophilias andpregnancies complicated with ischemic placental diseases, in Turkishwomen. This is a case control study comprising 140 women with ischemicplacental disease and 60 uncomplicated pregnant women. Parametersincluding haemoglobin, platelet count, uric acid, vitamin B12, folic acid,copper, homocysteine, plasminogen activator inhibitor-1, fibrinogen, proteinS, protein C, activated protein C resistance values were significantly changedin women with ischemic placental disease when compared to those withnormal pregnancies.The association between thrombophilia and ischemic pregnancy diseases isstronger than suggested previously. Furthermore, copper is selectivelyelevated in complicated pregnancies

The retrospective evaluation of patientswith acute bronchiolitis

Amaç: Bronsiolit, küçük hava yollarının inflamatuar obstrüksiyonundan kaynaklanan ve özellikle 6 aydan küçük çocuklarda en sık hospitalizasyon nedeni olan bir hastalıktır. Bu çalısmada, klinigimize bronsiolit nedeniyle kabul edilen olguların demografik özellikleri, klinik bulguları, tedavisi ve prognozu analiz edildi. Bulgular: Olguların %59,7'si (n=40) erkek, %40,3'ü (n=37) kız olup, %40,3'ü kıs, %29,9'u ilkbahar, %23,9'u sonbahar, %6'sı yaz mevsiminde hastanemize kabul edildi. En büyük hasta gurubunu 3-6 aylık bebekler (%35,8) olusturmaktaydı. Ilk basvuru sikayetleri %85'inde öksürük, %53,7'sinde hırıltı ve %34,3'ünde atesti. Atopi öyküsü üç ve daha fazla atak geçirenlerde %41.6, bir ve iki atak geçirenlerde %20olarak saptandı. Sonuç: Ailede atopi öyküsü bulunmasının bronsiolitli olgularda atak sayısını ve steroid gereksinimini arttırdıgı görüldü.Aim: Bronchiolitis is an under respiratory tract disorder which is caused by the inflammatory obstruction of the small airways. It is also the most common reason for hospitalization of children younger than 6 months. In this study, demographic characteristics, clinical symptoms, treatment and prognoses of patients who had been admitted to our clinic due to bronchiolitis were investigated. Findings: 59.7% of patients were male, and 40.3% were female. 40.3% were admitted to our hospital in winter, 29.5% in spring, 23.6% in fall and 6% in summer. The largest group of patients consisted of infants between 3-6 months (35.9%). Initial complaints were coughing in 85%, wheezing in 53.7% and fever in 34.3%. Of the patients history of atopy was determined more frequently (41.6%) among those who suffered from three or more attacks compared with patients who experienced one to two attacks (20%). Result: A history of atopy in the patient's family increases the number of bronchiolitis attacks and the need for steroid

Henoch-Schonlein purpuralı hastaların analizi

Amaç: HSP'li hastalarımızın epidemiyolojik ve klinik özellikleri, laboratuar bulguları ve hastalıgın seyrinin incelenmesi amaçlandı. Yöntem: 2000-2006 yılları arasında, hastanemiz Çocuk Saglıgı ve Hastalıkları Klinigi'nde Henoch-Schonlein Purpurası tanısı alan ve izlenen 45 hasta retrospektif olarak incelendi. Bulgular: Hastaların 27 (%60,0)'si kız, 18 (%40,0)'i erkek, kız / erkek oranı 1.5 idi.Yas ortalaması 6 yas 9 ay (8 ay-14 yas) olarak saptandı. Basvuru sikayetleri sıklık sırasına göre döküntü (%100), yürüyememe ve/veya eklem agrısı (%71,1) ve karın agrısı (%40,0) idi. Hastaların % 57,7'inde ortalama 12 gün önce geçirilmis enfeksiyon öyküsü tespit edildi. Fizik muayenede purpurik döküntü (alt ekstremite ve gluteal bölgede %100, yaygın %11,1), artrit (32 hastada, %71,1, en sık ayak bilegi ve diz eklemlerinde), ates (9 hastada, %20,0) bulundu. Laboratuar bulguları anemi (8/45 hasta, %17,7), lökositoz (6/45 hasta, %13,3), trombositoz (16/45 hasta, %35,5), sedimentasyon yüksekligi (16/25 hasta, %64,0), CRP pozitifligi (33/34 hasta, %97,0), hematüri (4/45 hasta, %8,8), proteinüri (2/45 hasta, %,4,4), gaitada gizli kan pozitifligi (14/42 hasta, %33,3) bulundu. Hematüri ve proteinüri devam etmedigi için hiçbir hastada böbrek biyopsisine gerek duyulmadı. Gastrointestinal sistem tutulumu oldugu düsünülen 17 hastaya steroid tedavisi baslandı ve ortalama 9.1 gün kullanıldı. Perforasyon, invaginasyon gözlenmedi. Ortalama 15. günde 9 hastada relaps görüldü. Santral sinir sistemi tutulumu hiçbir hastada yoktu. Sonuç: Henoch-Schonlein Purpurası çocukluk çagında sık görülen benign karakterli bir hastalık olup komplikasyon ve sekel oranı oldukça düsüktür.Aim: The aim of this study was to investigate the clinical and epidemiologic features, laboratory finding and outcome of disease in our patients with Henoch-Schönlein purpura. Methods: Fourty-five patients with Henoch-Schönlein purpura who were diagnosed and observed in our department of pediatrics between 2000-2006 were retrospectively evaluated. Results: Twentyseven (60.0%) of the patients were female and 18 (40.0%) were male, female to male ratio was1.5. Mean age of the patients was 6 year 9 months (8 months-14 years). İnitial symptoms and findings in the time of admission with decreasing frequency were purpura (100%), disability to walk and/or arthralgia (71.1%) ve stomachache (40.0%). An infection history was present in 57.7% of the patients in the last 12 days. In physical examination, purpura (lower extremity and hips 100%, diffuse 11.1%), arhtritis (32 patients, 71.1%, mostly diffused on ankle and knee), fever (9 patients, 20,0%) were discovered. Anaemia (8/45 patients, 17.7%), leukocytosis (6/45 patients, 13.3%), trombocytosis (16/45 patients, 35.5%), increased erythrocyte sedimentation rate (16/25 patients, 64.0%), positive CRP (33/34 patients, 97.0%), hematuria (4/45 patients, 8.8%), proteinuria (2/45 patients, 4.4%), positive fecal blood tests (14/42 patients, 33.3%) were determined. Renal biopsy was not needed as there was no persistant hematuria and proteinuria. 17 patients who had gastrointestinal involvement were treated with steroid therapy for a mean period of 9.1 days. Perforation and invagination was not observed. Relapse was seen in 9 patients. (mean duration 15th day). There was no nervous system involvement in any patients. Conclusion: Henoch-Schonlein Purpura is a frequent benign disease of childhood. Complicatios and sequeles are infrequent

Single and double injection paravertebral block comparison in reduction mammaplasty cases: a randomized controlled study

Background This study compares the analgesic effects and dermatomal blockade distributions of single and double injection bilateral thoracic paravertebral block (TPVB) techniques in patients undergoing reduction mammaplasty. Methods After obtaining ethics committee approval, 60 patients scheduled for bilateral reduction mammaplasty were included in the study. Preoperatively, the patients received one of single (Group S: T3–T4) or double (Group D: T2–T3 & T4–T5) injection bilateral TPVBs using bupivacaine 0.375% 20 ml per side. All patients were operated under general anesthesia. The T3–T6 dermatomal blockade distributions on the midclavicular line were followed by pin-prick test for 30 min preoperatively and 48 h postoperatively. All patients received paracetamol 1 g when numeric rating scale (NRS) pain score was ≥ 4, and also tramadol 1 mg/kg when NRS was ≥ 4 again after 1 h. The primary endpoint was NRS pain scores at postoperative 12th h. The secondary endpoints were dermatomal blockade distributions and NRS scores through the postoperative first 48 h, time until first pain and the analgesic consumption on days 1 and 2. Results Fifty-two patients completed the study. The NRS pain scores at 12th h were similar (right side: P = 0.100, left side: P = 0.096). The remaining NRS scores and other parameters were also comparable within the groups (P ≥ 0.05). Only single injection TPVB application time was shorter (P < 0.001). Conclusions The single injection TPVB technique provided sufficient dermatomal distribution and analgesic efficacy with the advantages of being faster and less invasive

Growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula in infants with cow’s milk protein allergy

ObjectiveTo evaluate growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula (eHCF) in infants with cow’s milk protein allergy (CMPA).MethodsA total of 226 infants (mean ± SD age: 106.5 ± 39.5 days, 52.7% were girls) with CMPA who received eHCF comprising at least half of the daily dietary intake were included. Data on anthropometrics [weight for age (WFA), length for age (LFA) and weight for length (WFL) z-scores] were recorded at baseline (visit 1), while data on infant feeding and stool records, anthropometrics and Infant Feeding and Stool Patterns and Formula Satisfaction Questionnaires were recorded at visit 2 (on Days 15 ± 5) and visit 3 (on Days 30 ± 5).ResultsFrom baseline to visit 2 and visit 3, WFA z-scores (from −0.60 ± 1.13 to −0.54 ± 1.09 at visit 2, and to −0.44 ± 1.05 at visit 3, p &lt; 0.001) and WFL z-scores (from −0.80 ± 1.30 to −0.71 ± 1.22 at visit 2, and to −0.64 ± 1.13 at visit 3, p = 0.002) were significantly increased. At least half of infants never experienced irritability or feeding refusal (55.7%) and spit-up after feeding (50.2%). The majority of mothers were satisfied with the study formula (93.2%), and wished to continue using it (92.2%).ConclusionsIn conclusion, eHCF was well-accepted and tolerated by an intended use population of infants  ≤ 6 months of age with CMPA and enabled adequate volume consumption and improved growth indices within 30 days of utilization alongside a favorable gastrointestinal tolerance and a high level of parental satisfaction